dr. rugo discusses advancements with biosimilars
Published 6 years ago • 89 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:37
dr. rugo discusses the regulatory process behind biosimilars
-
1:43
dr. rugo discusses the equivalency of trastuzumab biosimilars
-
1:53
dr. rugo discusses a comparative review of trastuzumab biosimilars
-
1:35
dr. rugo on the optimal setting for biosimilar evaluation
-
3:04
dr. rugo on 20-year span of breast cancer advancements
-
29:26
predicting outcomes in ra - the role of biomarkers
-
39:59
seronegative rheumatoid arthritis: biomarkers for diagnosis webinar
-
1:26:16
15 years of biosimilars - online webinar
-
1:15
dr. rugo discusses the future of angiogenesis in breast cancer
-
1:30
dr. hope rugo on trastuzumab biosimilar in her2-positive breast cancer
-
0:59
dr. hope rugo on safety of trastuzumab biosimilar for her2 breast cancer
-
0:52
dr. rugo discusses guidelines for metastatic breast cancer management
-
1:00
dr. dang on the significance of the myl-1401o biosimilar in her2-positive metastatic breast cancer
-
0:59
dr. verma discusses biosimilars for trastuzumab
-
1:48
dr. markman on the concept of biosimilars in oncology
-
1:42
dr. rugo on chemotherapy for metastatic breast cancer
-
1:57
dr. rugo on results of oral paclitaxel with encequidar in metastatic breast cancer
-
1:11
dr. hurvitz on importance of biosimilars in her2 breast cancer
-
1:36
dr. rugo on the efficacy of bevacizumab in breast cancer
-
1:22
dr. rugo on resistance to cdk4/6 inhibitors in hr breast cancer
-
0:55
dr. rugo on the future of extended adjuvant hormone therapy for breast cancer
-
1:39
dr. rugo on anti-angiogenesis therapy response predictors